Utilize este identificador para referenciar este registo:
https://hdl.handle.net/10316/109389
Título: | Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis | Autor: | Coimbra, Susana Figueiredo, Américo Santos-Silva, Alice |
Palavras-chave: | interleukin-17; interleukin-17 receptor; monoclonal antibody; T helper 17 pathway | Data: | 2014 | Editora: | Dove Medical Press Ltd | Título da revista, periódico, livro ou evento: | Core Evidence | Volume: | 9 | Resumo: | Advances in knowledge regarding the pathogenesis of psoriasis have allowed the development of a new class of agents known as biologic drugs. Data confirm that T helper (Th)17 and interleukin (IL)-17 signaling has a crucial role in the pathogenesis of the disease. High levels of IL-17 and Th17-related cytokines have been reported in psoriasis, leading to the suggestion of agents targeting IL-17 as a potential therapeutic strategy in psoriasis. Brodalumab is a human monoclonal antibody that targets IL-17 receptor A, blocking the effects of IL-17A, IL-17F, and IL-17E. Data from Phase I and Phase II clinical trials indicate that brodalumab has a favorable safety and tolerability profile, with strong clinical activity, suggesting that it is a potential tool for use in the treatment of moderate-to-severe psoriasis. | URI: | https://hdl.handle.net/10316/109389 | ISSN: | 1555-1741 | DOI: | 10.2147/CE.S33940 | Direitos: | openAccess |
Aparece nas coleções: | FMUC Medicina - Artigos em Revistas Internacionais |
Ficheiros deste registo:
Ficheiro | Descrição | Tamanho | Formato | |
---|---|---|---|---|
Brodalumab-An-evidencebased-review-of-its-potential-in-the-treatment-of-moderatetosevere-psoriasisCore-Evidence.pdf | 465.07 kB | Adobe PDF | Ver/Abrir |
Visualizações de página
38
Visto em 8/mai/2024
Downloads
6
Visto em 8/mai/2024
Google ScholarTM
Verificar
Altmetric
Altmetric
Este registo está protegido por Licença Creative Commons